Contact
searchSearch
HMP Global
Login

Skin Cancer

Farberg
Videos
Co-Managing Advanced Skin Cancer: Immunotherapy Insights
01/25/2024
Aaron S. Farberg, MD
In this interview, Dr Aaron Farberg explored key factors in advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
In this interview, Dr Aaron Farberg explored key factors in advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
In this interview, Dr Aaron...
01/25/2024
The Dermatologist
From The Dermatologist
Trending From ACCC
Improving the Care of Patients With Advanced Nonmelanoma Skin Cancers
02/06/2023
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of...
02/06/2023
Journal of Clinical Pathways
Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Conference Coverage
Toxicity Costs Among Patients With Melanoma Receiving Ipilimumab and Nivolumab
07/14/2021
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of...
07/14/2021
Journal of Clinical Pathways
Research Reports
Pediatric Sunscreen Coverage by Medicaid as a Primary Prevention Strategy to Reduce Melanoma Burden: A Cost-Effectiveness Analysis
04/22/2021
Christine T. Lauren, MD; Richard D. Carvajal, MD; Connor Stonesifer, BA; Chin Hur, MD, MPH; Robert Stern, MD; Daniel C. Malone, RPh, PhD, FAMCP; Larisa J. Geskin, MD; Megan H. Trager, MD; Dawn Queen, MD
Abstract: Melanoma treatment costs continue to rise. Sunscreen is a photoprotective tool that may reduce the incidence of melanoma but can be cost prohibitive for lower socioeconomic populations. New York State...
Abstract: Melanoma treatment costs continue to rise. Sunscreen is a photoprotective tool that may reduce the incidence of melanoma but can be cost prohibitive for lower socioeconomic populations. New York State...
...
04/22/2021
Journal of Clinical Pathways
News
Medicare FFS Pricing Incentivizes Use of Mohs Micrographic Surgery Over Other Skin Cancer Procedures
12/03/2020
12/03/2020
Journal of Clinical Pathways
Research in Review
Continued Nivolumab After Progression May Improve Outcomes in Melanoma
07/03/2017
Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety, according to an original investigation published in JAMA...
Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety, according to an original investigation published in JAMA...
...
07/03/2017
Journal of Clinical Pathways
Research in Review
Does Delayed Lymph Node Biopsy Affect Survival Rates in Melanoma?
06/29/2017
Recent research compared survival outcomes of patients newly diagnosed with melanoma who received a sentinel lymph node biopsy within 30 days and those who received biopsy after 30 days, published in the Journal of...
Recent research compared survival outcomes of patients newly diagnosed with melanoma who received a sentinel lymph node biopsy within 30 days and those who received biopsy after 30 days, published in the Journal of...
Recent...
06/29/2017
Journal of Clinical Pathways
Research in Review
Imaging Needed to Monitor Melanoma Brain Metastases During PD-1 Therapy
06/03/2017
Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at...
Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at...
...
06/03/2017
Journal of Clinical Pathways
Research in Review
Burden on Treatment Costs Impact Quality of Life Among Melanoma Survivors
06/03/2017
Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...
Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...
...
06/03/2017
Journal of Clinical Pathways
Research in Review
Advanced Melanoma Increases Psychological Burden in Patients
05/25/2017
Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies, according to research that will be presented at the 2017 ASCO Annual Meeting...
Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies, according to research that will be presented at the 2017 ASCO Annual Meeting...
Stage...
05/25/2017
Journal of Clinical Pathways

Expert Insights

Farberg
Videos
Co-Managing Advanced Skin Cancer: Immunotherapy Insights
01/25/2024
Aaron S. Farberg, MD
In this interview, Dr Aaron Farberg explored key factors in advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
In this interview, Dr Aaron Farberg explored key factors in advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
In this interview, Dr Aaron...
01/25/2024
The Dermatologist
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
  Key Clinical Summary Dual-targeting CAR T-cell therapy shows promise: Findings from the phase 2 ZUMA-14 trial suggest that combining axicabtagene ciloleucel (axi-cel) with rituximab may improve response durability by...
  Key Clinical Summary Dual-targeting CAR T-cell therapy shows promise: Findings from the phase 2 ZUMA-14 trial suggest that combining axicabtagene ciloleucel (axi-cel) with rituximab may improve response durability by...
  Key Clinical...
07/06/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration: Part 2
06/17/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores...
06/17/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration
06/17/2026
Kishen Patel, PharmD
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel,...
06/17/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Interview
Cardiopulmonary Comorbidities and CRS Risk After CAR T-Cell Therapy in DLBCL: Insights From Real-World Data
06/11/2026
Heidi Cho, MD
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that...
06/11/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Diffuse Large B-Cell Lymphoma, DLBCL
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis
05/26/2026
Nishanth Thalambedu, MD
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part II
05/26/2026
Mark A. Socinski, MD
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of...
05/26/2026
Journal of Clinical Pathways

Newsfeed

Conference Coverage
Toxicity Costs Among Patients With Melanoma Receiving Ipilimumab and Nivolumab
07/14/2021
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of...
07/14/2021
Journal of Clinical Pathways
Conference Coverage
Using Real-World Data to Improve HRR Testing Rates Among Patients With mCRPC
07/17/2026
Andy Osterland, PharmD, MS
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS,...
07/17/2026
Journal of Clinical Pathways
News
APP-Led Benign Hematology Consults Improve Access in Community Oncology, Study Finds
07/16/2026
Grace Taylor, MS, MA
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The...
07/16/2026
Journal of Clinical Pathways
News
Evolutions in Frontline Treatment Patterns for Newly Diagnosed MM
07/15/2026
Rebecca Amrick
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a...
07/15/2026
Journal of Clinical Pathways
News
JAK Inhibitors Demonstrate Improved Efficacy but Worse Toxicity in Myelofibrosis
07/13/2026
Rebecca Amrick
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase...
07/13/2026
Journal of Clinical Pathways
Jessica Paulus Headshot
Conference Coverage
Distress Thermometer Scores Highlight Association Between Psychosocial Distress and Survival Outcomes for Cancer Patients
07/13/2026
Jessica Paulus, ScD
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses...
07/13/2026
Journal of Clinical Pathways
News
Circulating Tumor DNA Could Improve Minimal Residual Disease Detection for Ovarian Cancer
06/26/2026
Rebecca Amrick
Circulating tumor DNA shows promise as a non-invasive alternative to second look laparoscopy at detecting minimal residual disease detection and predicting survival outcomes for patients with ovarian cancer.
Circulating tumor DNA shows promise as a non-invasive alternative to second look laparoscopy at detecting minimal residual disease detection and predicting survival outcomes for patients with ovarian cancer.
Circulating tumor DNA shows...
06/26/2026
Journal of Clinical Pathways
News
IOTA ADNEX Model Outperforms Current Ovarian Cancer Triage Standard
06/23/2026
Hannah Musick
The International Ovarian Tumour Analysis Assessment of Different Neoplasias (IOTA ADNEX) ultrasound model more than doubled ovarian cancer detection sensitivity compared with the current Risk of Malignancy Index standard, supporting its...
The International Ovarian Tumour Analysis Assessment of Different Neoplasias (IOTA ADNEX) ultrasound model more than doubled ovarian cancer detection sensitivity compared with the current Risk of Malignancy Index standard, supporting its...
The International Ovarian Tumour...
06/23/2026
Journal of Clinical Pathways
News
CAR T Therapy Demonstrates Improved Efficacy but Increased Toxicity in Patients With Relapsed or Refractory MM
06/22/2026
Rebecca Amrick
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR)...
06/22/2026
Journal of Clinical Pathways
Jessica Paulus Headshot
Conference Coverage
Closing the Gap Between Clinical Guideline Updates and Real-World Adoption for HER2-Low Therapies
06/17/2026
Jessica Paulus, ScD
Jessica Paulus, ScD, discusses the impact of education on increasing rates of human epidermal growth factor receptor 2 (HER2)-low therapy for patients with metastatic breast cancer.
Jessica Paulus, ScD, discusses the impact of education on increasing rates of human epidermal growth factor receptor 2 (HER2)-low therapy for patients with metastatic breast cancer.
Jessica Paulus, ScD, discusses...
06/17/2026
Journal of Clinical Pathways
News
Frailty Predicts Fewer Days at Home After Ovarian Cancer Surgery
06/17/2026
Hannah Musick
Frailty—not age alone—was the strongest predictor of reduced time spent alive and at home during the year after ovarian cancer surgery, with frail older adults experiencing substantially worse long-term recovery and higher mortality than...
Frailty—not age alone—was the strongest predictor of reduced time spent alive and at home during the year after ovarian cancer surgery, with frail older adults experiencing substantially worse long-term recovery and higher mortality than...
Frailty—not age alone—was the...
06/17/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use